Recombinant Orconectes limosus Orcomyotropin

What is Orconectes limosus Orcomyotropin and how was it first discovered?

Orcomyotropin is a novel octapeptide (FDAFTTGFamide) first identified from extracts of hindguts of the crayfish Orconectes limosus. It was discovered using an isolated hindgut contractility bioassay, high-performance liquid chromatography, microsequencing, and mass spectrometry techniques. Orcomyotropin represents a crustacean member of the GF-amide family of myotropic and/or allatotropic neuropeptides found across annelids, molluscs, and insects . The peptide was isolated during investigations of hindgut-contracting materials, where researchers were initially studying orcokinin analogues but discovered this distinct peptide with potent myostimulatory effects.

What is the structural composition of orcomyotropin and how does it compare to other neuropeptides?

Orcomyotropin is an octapeptide with the amino acid sequence FDAFTTGFamide. It belongs to the GF-amide family of neuropeptides, characterized by a glycine-phenylalanine-amide C-terminal sequence. While orcokinins (another family of neuropeptides found in the same organism) are tridecapeptides with 13 amino acids, orcomyotropin has only 8 amino acids but demonstrates higher potency in hindgut bioassays . The C-terminal amidation is a common post-translational modification in many bioactive peptides and is crucial for biological activity.

What are the main physiological functions of native orcomyotropin?

Native orcomyotropin demonstrates strong inotropic (contractile force-enhancing) actions on crayfish hindguts. It shows remarkably high potency with a threshold concentration of approximately 5×10^-12 mol l^-1, which is significantly lower than the 10^-10 mol l^-1 threshold for orcokinins. At a concentration of 10^-9 mol l^-1, orcomyotropin produces approximately a fivefold increase in contraction amplitude of the hindgut muscles . Immunocytochemical studies have shown that orcomyotropin is co-localized with Asn13-orcokinin in approximately 80-90 neurons of the terminal abdominal ganglion that innervate the entire hindgut muscularis via the intestinal nerve. These neurons form elaborate terminal branches preferentially on longitudinal hindgut muscles .

Which expression systems are most effective for recombinant orcomyotropin production?

For recombinant orcomyotropin production, bacterial expression systems, particularly Escherichia coli, represent the most commonly used platform due to their simplicity, cost-effectiveness, and high yield potential. When designing expression strategies, researchers should consider using specialized strains optimized for disulfide bond formation and proper folding of small peptides.

For more complex post-translational modifications, including C-terminal amidation (critical for orcomyotropin bioactivity), eukaryotic systems such as yeast (Pichia pastoris) or insect cell lines (Sf9 or High Five cells with baculovirus vectors) may be preferable. These systems can better reproduce the native post-translational modifications of the peptide, which are essential for full biological activity.

The experimental design should include:

• Codon optimization for the chosen expression host

• Fusion with solubility-enhancing partners (MBP, SUMO, or thioredoxin)

• Incorporation of precision protease cleavage sites

• Strategies for C-terminal amidation, which is crucial for orcomyotropin's biological function

What purification strategies yield the highest recovery and purity of recombinant orcomyotropin?

Efficient purification of recombinant orcomyotropin requires a multi-step approach designed to accommodate its small size (octapeptide) and specific characteristics. Based on the isolation methods used for native orcomyotropin, the following purification strategy is recommended:

• Initial capture: Affinity chromatography using the fusion tag (His-tag, GST, or MBP)

• Tag removal: Site-specific protease cleavage (TEV or PreScission protease)

• Intermediate purification: Ion-exchange chromatography

• Polishing: Reversed-phase HPLC using C18 columns with acetonitrile gradients in 0.1% TFA

The final reverse-phase HPLC step is particularly critical as it mimics the separation technique that successfully isolated native orcomyotropin from crayfish hindgut extracts . For analytical confirmation of purity and identity, mass spectrometry should be employed, targeting the expected molecular weight of 1027.1 Da (the mass of the FDAFTTGFamide sequence with C-terminal amidation).

How can researchers verify the structural integrity and bioactivity of recombinant orcomyotropin?

Verification of recombinant orcomyotropin requires both structural and functional analyses:

Structural verification:

• Mass spectrometry (MS): Electrospray ionization MS or MALDI-TOF MS to confirm exact molecular weight

• Peptide sequencing: Edman degradation or tandem MS techniques

• Circular dichroism: To evaluate secondary structure elements

• NMR spectroscopy: For detailed structural characterization

Functional verification:

• Hindgut contractility assay: The most relevant bioassay, measuring the peptide's capacity to enhance contractile amplitude of isolated crayfish hindguts

• Dose-response curves: Should demonstrate threshold activity at approximately 5×10^-12 mol l^-1 and a fivefold increase in contraction amplitude at 10^-9 mol l^-1

• Comparative analysis: Activity comparison with synthesized native peptide in parallel assays

The hindgut contractility assay remains the gold standard for functional verification, as it was the original bioassay used to discover and characterize orcomyotropin .

What is the optimal experimental design for studying orcomyotropin's effects on hindgut contractility?

The optimal experimental design for studying orcomyotropin's effects on hindgut contractility should follow a quasi-experimental approach with appropriate controls. Based on the methodologies described in the literature and quasi-experimental design principles, the following approach is recommended:

Study design: One-group pretest-posttest design with repeated measurements (Design A2 or A3 from quasi-experimental design hierarchy)

Procedure:

• Dissect and isolate hindguts from Orconectes limosus crayfish

• Mount the hindgut in a perfusion chamber with physiological saline

• Record baseline spontaneous contractions for 10-15 minutes (O1)

• Apply incrementally increasing concentrations of recombinant orcomyotropin (X)

• Record contractile responses at each concentration (O2, O3, etc.)

• Wash out the peptide and record recovery phase (optional)

Parameters to measure:

• Contraction frequency (contractions per minute)

• Contraction amplitude (force or displacement)

• Contraction duration

• Area under the curve (integrated contractile activity)

This approach allows for the establishment of complete dose-response relationships and determination of EC50 values for comparative analysis with native peptide or other myotropic agents .

How can immunocytochemical techniques be applied to localize orcomyotropin-containing neurons?

Immunocytochemical techniques are critical for mapping the distribution of orcomyotropin in the crayfish nervous system. Based on previous successful approaches, researchers should implement the following protocol:

Antibody generation:

• Produce specific antibodies against synthetic orcomyotropin conjugated to a carrier protein

• Validate antibody specificity through preabsorption controls using synthetic orcomyotropin (20 nmol of orcomyotropin per μl of antiserum should be sufficient to block immunostaining completely)

Tissue preparation:

• Dissect the terminal abdominal ganglion and hindgut from crayfish

• Fix tissues in paraformaldehyde (4%) in phosphate buffer

• Process for whole-mount immunocytochemistry or prepare cryosections

Immunostaining procedure:

• Block non-specific binding sites with normal serum

• Incubate with primary anti-orcomyotropin antibodies (overnight at 4°C)

• Visualize using fluorescent-labeled secondary antibodies or the ABC technique

• Perform double-labeling with anti-Asn13-orcokinin antibodies to demonstrate co-localization

This approach has revealed that orcomyotropin is co-localized with Asn13-orcokinin in approximately 80-90 neurons of the terminal abdominal ganglion that innervate the entire hindgut muscularis via the intestinal nerve, with elaborate terminal branches preferentially on longitudinal hindgut muscles .

What bioassay systems can effectively differentiate between orcomyotropin and orcokinin activities?

To effectively differentiate between orcomyotropin and orcokinin activities, researchers should employ multiple bioassay systems with distinctive response patterns. The following comparative bioassay approach is recommended:

Table 1: Comparative Bioassay Systems for Differentiating Orcomyotropin and Orcokinin Activities

The crayfish hindgut contractility assay provides the clearest differentiation, with orcomyotropin showing approximately 100-fold higher potency than orcokinins . The lack of orcomyotropin activity on semi-isolated crayfish hearts and locust oviducts further helps distinguish it from other myotropic peptides that may affect these tissues.

What molecular mechanisms underlie orcomyotropin's effects on hindgut muscle contractility?

The molecular mechanisms underlying orcomyotropin's potent effects on hindgut muscle contractility likely involve several signaling pathways:

• Receptor activation: Orcomyotropin likely binds to G-protein coupled receptors (GPCRs) on hindgut muscle cells, as is common for neuropeptides of the GF-amide family.

• Signal transduction pathways: Based on studies of similar myotropic peptides, orcomyotropin likely activates:

  • Phospholipase C pathway → IP3 production → calcium release from intracellular stores

  • Possibly modulates cAMP levels through adenylyl cyclase regulation

  • May activate protein kinase C, leading to phosphorylation of contractile proteins

• Calcium dynamics: Orcomyotropin likely increases cytosolic calcium concentration through:

  • Release from sarcoplasmic reticulum

  • Possibly enhances calcium influx through L-type calcium channels

  • May modulate calcium sensitivity of the contractile apparatus

• Muscle effector mechanisms: The peptide ultimately enhances:

  • Actomyosin cross-bridge cycling

  • Coordination of contraction across muscle fibers

  • Possibly affects pacemaker activity in hindgut muscle cells

The remarkable potency of orcomyotropin (threshold concentration ~5×10^-12 mol l^-1) suggests high-affinity receptor binding and efficient signal amplification mechanisms .

How do structure-activity relationships inform the design of orcomyotropin analogs with enhanced properties?

Structure-activity relationship (SAR) studies are essential for understanding the molecular determinants of orcomyotropin's bioactivity and designing analogs with enhanced properties. The following systematic approach is recommended:

• Terminal modification studies:

  • C-terminal amidation is likely essential (as in many bioactive peptides)

  • N-terminal modifications to assess the importance of the phenylalanine residue

• Alanine scanning:

  • Sequential replacement of each amino acid with alanine to identify critical residues

  • Expected key residues: The phenylalanine residues at positions 1 and 8, and the aspartic acid at position 2

• Conservative substitutions:

  • Replacement of phenylalanine with other aromatic amino acids (Tyr, Trp)

  • Substitution of aspartic acid with glutamic acid

  • Glycine replacement with other small amino acids

• Conformational constraints:

  • Introduction of disulfide bridges or other cyclization strategies

  • Proline substitutions to introduce specific turns

• D-amino acid substitutions:

  • To enhance proteolytic stability

  • To explore bioactive conformations

Each analog should be tested in the hindgut contractility assay to generate comprehensive structure-activity data. This information can then guide the design of orcomyotropin analogs with enhanced potency, selectivity, stability, or other desired properties.

What evolutionary insights can be gained from comparative studies of orcomyotropin across crustacean species?

Comparative studies of orcomyotropin across crustacean species can provide valuable evolutionary insights into neuropeptide conservation and diversification. Key research directions include:

• Phylogenetic distribution:

  • Survey of orcomyotropin presence across decapod crustaceans and other arthropod groups

  • Correlation with hindgut neuroanatomy and physiology

  • Relationship to habitat and feeding behaviors

• Sequence conservation:

  • Identification of invariant residues across species (likely the GF-amide motif)

  • Variable regions that may reflect species-specific adaptations

  • Correlation between sequence divergence and phylogenetic distance

• Functional conservation:

  • Comparative potency in cross-species bioassays

  • Species-specific receptor binding profiles

  • Tissue specificity patterns across evolutionary lineages

• Genetic organization:

  • Genomic structure of orcomyotropin precursor genes

  • Regulatory elements controlling expression patterns

  • Evolutionary relationships to other GF-amide family neuropeptide genes

Orcomyotropin represents a novel crustacean member of the GF-amide family of neuropeptides found across multiple invertebrate phyla , suggesting ancient evolutionary origins. Comparative studies could illuminate how this signaling system has been maintained or adapted throughout arthropod evolution.

What are common challenges in recombinant orcomyotropin expression and how can they be overcome?

Recombinant expression of small peptides like orcomyotropin presents several technical challenges that researchers should anticipate and address:

Challenge 1: Proteolytic degradation

• Solution: Use protease-deficient host strains, incorporate protease inhibitors during purification, and optimize growth conditions (lower temperature, reduced induction time)

• Alternative: Express with N-terminal fusion partners (SUMO, MBP) that enhance stability

Challenge 2: Formation of inclusion bodies

• Solution: Lower induction temperature (16-20°C), reduce inducer concentration, use solubility-enhancing fusion tags

• Alternative: Develop refolding protocols from inclusion bodies using stepwise dialysis

Challenge 3: Low yield of active peptide

• Solution: Optimize codon usage, use strong promoters, and test multiple expression systems

• Alternative: Chemical synthesis for small peptides like orcomyotropin (8 amino acids) may be more cost-effective than recombinant production

Challenge 4: C-terminal amidation

• Solution: Co-express with peptidylglycine α-amidating monooxygenase (PAM) in eukaryotic systems

• Alternative: Use enzymatic amidation in vitro after purification

Challenge 5: Confirmation of correct folding

• Solution: Compare with synthetic standards using analytical techniques (HPLC, MS) and bioassays

• Alternative: Structural analysis by NMR or circular dichroism

How can researchers troubleshoot inconsistent results in orcomyotropin bioassays?

Inconsistent results in orcomyotropin bioassays can arise from multiple sources. The following troubleshooting guide addresses common issues:

Table 2: Troubleshooting Guide for Orcomyotropin Bioassays

When experimenting with hindgut contractility assays, researchers should consider using a quasi-experimental design with multiple observations before and after intervention to increase the robustness of their findings .

What strategies can enhance the reproducibility and reliability of orcomyotropin research?

Enhancing reproducibility and reliability in orcomyotropin research requires systematic attention to multiple factors:

• Standardized reporting:

  • Adopt ARRIVE guidelines for animal experiments

  • Report detailed methods including animal source, sex, size, and acclimation conditions

  • Provide complete peptide characterization data (sequence, purity, MS confirmation)

• Experimental design:

  • Implement higher-level quasi-experimental designs with appropriate controls

  • Use double-pretest designs to address regression to the mean concerns

  • Calculate appropriate sample sizes through power analysis

• Validation approaches:

  • Independent replication across different laboratories

  • Cross-validation with complementary techniques

  • Use of positive and negative controls in all experiments

• Quality control measures:

  • Batch testing of recombinant peptide preparations

  • Regular calibration of equipment

  • Blinded analysis of results when possible

• Data sharing:

  • Deposit raw data in public repositories

  • Share detailed protocols through protocols.io or similar platforms

  • Pre-registration of experimental designs when applicable

Following these strategies will enhance the robustness and reproducibility of orcomyotropin research, addressing the broader reproducibility challenges in biomedical research.

What are the most promising applications of recombinant orcomyotropin in neuroscience research?

Recombinant orcomyotropin offers several promising applications in neuroscience research:

• Receptor deorphanization and characterization:

  • Identification of the specific G-protein coupled receptor(s) for orcomyotropin

  • Mapping receptor distribution in crustacean nervous systems

  • Comparison with receptors for other GF-amide family peptides

• Neural circuit mapping:

  • Using fluorescently labeled orcomyotropin to trace peptidergic circuits

  • Optogenetic targeting of orcomyotropin-expressing neurons

  • Activity mapping during feeding and digestive behaviors

• Comparative neurobiology:

  • Investigation of hindgut control mechanisms across crustacean species

  • Evolutionary studies of neuropeptide signaling systems

  • Exploration of conserved functions in other arthropods

• Neurophysiological tools:

  • Development of orcomyotropin-based probes for specific neuron populations

  • Creation of antagonists as pharmacological tools

  • Designer receptors exclusively activated by designed drugs (DREADD) based on orcomyotropin receptors

• Gut-brain axis research:

  • Investigation of feedback mechanisms between digestive function and central nervous system

  • Role in coordination of feeding, digestion, and elimination behaviors

  • Potential neuromodulatory roles beyond direct myotropic effects

These applications leverage the unique properties of orcomyotropin as a highly potent, tissue-specific neuropeptide with a defined neuroanatomical distribution .

How might orcomyotropin research contribute to understanding broader principles of neuropeptide signaling?

Orcomyotropin research has the potential to illuminate several fundamental principles of neuropeptide signaling:

• Signal amplification mechanisms:

  • Understanding how extraordinarily low concentrations (5×10^-12 mol l^-1) produce robust physiological effects

  • Elucidation of receptor-effector coupling efficiency

  • Investigation of second messenger cascades with high signal gain

• Co-transmission principles:

  • Mechanisms of co-release with orcokinin in the 80-90 neurons where they colocalize

  • Functional significance of peptide co-expression

  • Differential regulation of co-localized neuropeptide release

• Evolutionary conservation of signaling motifs:

  • Structural and functional comparisons across the GF-amide peptide family

  • Receptor evolution and ligand-receptor co-evolution

  • Convergent evolution of peptidergic control of visceral muscles

• Integration of multiple peptidergic inputs:

  • How muscles integrate signals from multiple myotropic peptides

  • Synergistic or antagonistic interactions between peptide systems

  • Temporal dynamics of multi-peptide signaling networks

• Structural determinants of receptor specificity:

  • Identification of key residues determining receptor binding and activation

  • Molecular basis for the higher potency compared to orcokinins

  • Structure-based design of selective agonists and antagonists

These broader principles derived from orcomyotropin research could inform our understanding of neuropeptide signaling across diverse physiological systems and species.

What interdisciplinary approaches could advance understanding of orcomyotropin's biological significance?

Advancing our understanding of orcomyotropin's biological significance requires interdisciplinary approaches that integrate multiple fields:

• Systems neuroscience and behavior:

  • Correlating orcomyotropin signaling with feeding and digestive behaviors

  • Investigation of hindgut motility patterns in intact animals

  • Potential role in defecation reflexes and temporal coordination of digestion

• Molecular evolution and comparative genomics:

  • Identification of orcomyotropin genes across crustacean genomes

  • Analysis of selection pressures on peptide sequence

  • Comparative studies of regulatory elements controlling expression

• Synthetic biology and bioengineering:

  • Development of genetically encoded biosensors for orcomyotropin

  • Creation of conditional expression systems for functional studies

  • Design of peptidomimetics with enhanced stability or specificity

• Computational neuroscience:

  • Modeling of hindgut neural circuits incorporating peptidergic signaling

  • Simulation of dose-response relationships and signal integration

  • Prediction of peptide-receptor interactions through molecular dynamics

• Translational approaches:

  • Investigation of similar peptide systems in mammalian hindgut

  • Potential relevance to gastrointestinal motility disorders

  • Comparative pharmacology with mammalian GI peptides

By integrating these diverse approaches, researchers can develop a comprehensive understanding of orcomyotropin's role within the broader context of neural control of digestive function and its evolutionary significance across species.